Gentileschi, S., Barreca, C., Bellisai, F., Biasi, G., Brizi, M.G., De Stefano, R., et al. (2016). Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. EXPERT OPINION ON BIOLOGICAL THERAPY, 16(10), 1311-1312 [10.1080/14712598.2016.1198765].

Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683

BELLISAI, FRANCESCA;FABBRONI, MARTA;FIORAVANTI, ANTONELLA;FRATI, ELENA;Vitale, Antonio;CANTARINI, LUCA;FREDIANI, BRUNO;GALEAZZI, MAURO
2016-01-01

Gentileschi, S., Barreca, C., Bellisai, F., Biasi, G., Brizi, M.G., De Stefano, R., et al. (2016). Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. EXPERT OPINION ON BIOLOGICAL THERAPY, 16(10), 1311-1312 [10.1080/14712598.2016.1198765].
File in questo prodotto:
File Dimensione Formato  
Frati ranking 1.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.17 MB
Formato Adobe PDF
1.17 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
FRATI-Switch from infliximab-Post--Print.pdf

accesso aperto

Descrizione: Accepted Manuscript
Tipologia: Post-print
Licenza: Creative commons
Dimensione 147.88 kB
Formato Adobe PDF
147.88 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/996417